Aspire-Lakewood Holdings, Inc. SEC filings ASBPW
Aspire-Lakewood Holdings, Inc. has 228 filings in SEC EDGAR's recent list, going back to Mar 16, 2021. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (auditor change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFR14A | Filing | May 12, 2026 | — |
| EFFECT | Filing | Apr 14, 2026 | — |
| CORRESP | Letter to the SEC | Apr 13, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2026 | — |
| EFFECT | Filing | Dec 12, 2025 | — |
| CORRESP | Letter to the SEC | Dec 11, 2025 | — |
| EFFECT | Filing | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| CORRESP | Letter to the SEC | May 28, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| EFFECT | Filing | Apr 21, 2025 | — |
| CORRESP | Letter to the SEC | Apr 18, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| 25-NSE | Delisting notice | Feb 19, 2025 | — |
| EFFECT | Filing | Jan 14, 2025 | — |
| CORRESP | Letter to the SEC | Jan 13, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| 425 | Filing | Dec 26, 2024 | — |
| CORRESP | Letter to the SEC | Dec 23, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 10, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2024 | — |
| CORRESP | Letter to the SEC | Nov 15, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| CORRESP | Letter to the SEC | Oct 24, 2024 | — |
| CORRESP | Letter to the SEC | Oct 23, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2024 | — |
| 425 | Filing | Oct 10, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 8, 2024 | — |
| 425 | Filing | Oct 4, 2024 | — |
| 425 | Filing | Sep 6, 2024 | — |
| 425 | Filing | Aug 30, 2024 | — |
| NT 10-Q | Filing | Aug 15, 2024 | Jun 30, 2024 |
| RW | Filing | Aug 2, 2024 | — |
| 425 | Filing | Jun 7, 2024 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| UPLOAD | Letter from the SEC | Jan 31, 2024 | — |
| 425 | Filing | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 23, 2024 | — |
| 425 | Filing | Dec 28, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2023 | — |
| EFFECT | Filing | Feb 17, 2022 | — |
| CERT | Filing | Feb 17, 2022 | — |
| 8-A12B | Form 8-a12b | Feb 17, 2022 | — |
| CORRESP | Letter to the SEC | Feb 15, 2022 | — |
| CORRESP | Letter to the SEC | Feb 15, 2022 | — |
| CORRESP | Letter to the SEC | Jan 6, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2021 | — |
| DRS/A | Filing | Sep 7, 2021 | — |
| DRS/A | Filing | May 20, 2021 | — |
| DRSLTR | Filing | May 19, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2021 | — |
| DRS | Filing | Mar 16, 2021 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ASBP (Nasdaq), ASBPW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Estero, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1847345
- Former names
- Aspire Biopharma Holdings, Inc. (until Sep 9, 2026); PowerUp Acquisition Corp. (until Feb 19, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.